Pillars of growth
Heavy bet for R&D
as a future
growth engine
Heavy bet on R&D
as a future
growth engine
Biosimilars
A great growth opportunity for ROVI in a market that totals more than 1,000 million euros in Europe.
Pharmaceutical products
Diversified portfolio of innovative own and licensed products protected by patents.
Low Molecular Weight Heparin
ROVI's principal product, a low-molecular-weight heparin developed in-house.
Contract manufacturing
High production capacity with four manufacturing plants for prefilled syringes and oral solid forms.
Rovi in figures
+19%
Net profit of the business without R&D in 2018
+42%
2018 LMWHglobal sales
56 countries
Bemiparim international presence with 22 international partners
6 plants
for manufacturing own and third-party products in Spain
€32,4 Mn
of investment in R&D in 2018 Commitment to innovation
7 countries
Direct presence through subsidiaries to market Enoxaparin
Information for investors
Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.
Last news on Rovi
11/04/2019
ROVI will market Tetridar® in Spain
ROVI will market Teva's medicine Tetridar® for the treatment of osteoporosis in adults in Spain
19/03/2019
Positive Topline Results from Phase 3 study of Doria® in Patients with Schizophrenia
Advanced Final Results from the Pivotal Study of its Once-monthly Injectable Antipsychotic show that Primary and Key Secondary Efficacy Endpoints Were Achieved with Both Doses Tested for the Treatment of Patients with Acute Exacerbation of Schizophrenia
Last annual report
Annual Report 2017
Last regular
public information